ERBB2 and breast carcinoma: In vivo and in vitro experiments show that inhibition of AR can reduce the growth of HER2+ breast cancer cells and inhibit the phosphorylation of HER2 and the activation of Akt and Erk but does not affect the expression of HER2 protein13.